Cell therapy (CAR-T) · Kills target cells, directed at CD33 · developed by Precigen
PRGN-3006 is an autologous T-lymphocyte preparation genetically modified to express an anti-CD33 chimeric antigen receptor, membrane-bound IL-15, and a safety switch. The CAR-T cells bind CD33-expressing tumor cells to induce selective toxicity, and are studied in acute myeloid leukemia and myelodysplastic syndromes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03927261 | Phase 1 | Acute Myeloid Leukemia | Active not recruiting | PGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.
See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PGEN catalysts and pipeline →